CareDx Inc (NASDAQ: CDNA) stock soared over 6% in pre-market trading on Thursday, following the company's impressive fourth-quarter 2024 financial results. The surge can be attributed to CareDx's robust performance, with the company reporting a 32% year-over-year increase in quarterly revenue to $86.6 million and achieving adjusted EBITDA of $9.8 million.
The healthcare company, which specializes in precision medicine solutions for transplant patients, has been capitalizing on strong demand for its testing services. This segment saw a 37% year-over-year growth, driven by a 14% increase in test volumes. Additionally, CareDx significantly expanded its payer coverage, adding millions of new commercially covered lives for its products.
CareDx's solid performance was further bolstered by its robust financial position, as the company ended 2024 with a strong cash balance of $261 million and no debt. This financial strength positions CareDx well for future growth initiatives and potential strategic opportunities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.